# REGENERON PHARMACEUTICALS, INC. (REGN) FY2025 Q1 Balance Sheet

- Company: REGENERON PHARMACEUTICALS, INC. (REGN)
- Period: As of 2025-03-31
- Filing: Q1 FY2025 10-Q, filed 2025-04-29, accession number 0001804220-25-000022
- Page: https://plicit.ai/financials/regn/fy2025-q1-balance-sheet
- Chart image: https://plicit.ai/charts/regn-fy2025-q1-balance-sheet-sankey.png

## Chart details

Balance sheet as of 2025-03-31. The chart shows assets, liabilities and equity at that date.

- **Assets**: 37,545,200,000 US dollars
- **Current assets**: 17,571,700,000 US dollars
- **Non-current assets**: 19,973,500,000 US dollars
- **Liabilities**: 8,157,600,000 US dollars
- **Current liabilities**: 3,566,600,000 US dollars
- **Non-current liabilities**: 4,591,000,000 US dollars
- **Equity**: 29,387,600,000 US dollars
- **Accounts receivable, net**: 5,561,000,000 US dollars
- **Marketable securities**: 5,259,200,000 US dollars
- **Inventories**: 3,192,400,000 US dollars
- **Cash and cash equivalents**: 3,090,200,000 US dollars
- **Prepaid expenses and other current assets**: 468,900,000 US dollars
- **Marketable securities**: 9,276,300,000 US dollars
- **Property, plant, and equipment, net**: 4,694,200,000 US dollars
- **Deferred tax assets**: 3,442,900,000 US dollars
- **Other noncurrent assets**: 1,393,100,000 US dollars
- **Intangible assets, net**: 1,167,000,000 US dollars
- **Accrued expenses and other current liabilities**: 2,241,800,000 US dollars
- **Accounts payable**: 705,500,000 US dollars
- **Deferred revenue**: 619,300,000 US dollars
- **Long-term debt**: 1,984,800,000 US dollars
- **Other noncurrent liabilities**: 1,674,400,000 US dollars
- **Finance lease liabilities**: 720,000,000 US dollars
- **Deferred revenue**: 211,800,000 US dollars
- **Retained earnings**: 32,384,400,000 US dollars
- **Additional paid-in capital**: 13,192,100,000 US dollars
- **Accumulated other comprehensive income (loss)**: 29,100,000 US dollars
- **Common stock - Common Stock**: 100,000 US dollars
- **Common stock - Class A Stock**: 0 US dollars
- **Preferred Stock, par value $.01 per share; 30.0 shares authorized; shares issued and outstanding - none**: 0 US dollars
- **Treasury Stock, at cost; 29.7 shares in 2025 and 28.2 shares in 2024**: negative 16,218,100,000 US dollars
- **Gross equity (calculated)**: 45,605,700,000 US dollars. Net equity plus the magnitudes of its negative contributions equals gross positive equity. The negative contributions enter this reconciliation as add-backs; their filed signs stay negative.

### Chart connections

- Assets equal liabilities plus consolidated equity. Consolidated equity includes noncontrolling interests when reported.
- Treasury shares and other negative equity contributions reduce equity.